🔗 Share this article Patients Coming Off Weight-Loss Injections Put On Weight Four Times Faster Than Those on Conventional Diets Weight management often requires ongoing approaches. Fresh analysis reveals that patients who come off new weight-loss injections like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens. Published data in a prominent medical journal shows that while obese individuals can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit. "People using such drugs must be cognizant of the danger of rapid weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb. That rate of recovery suggests a return to starting weight within about a year and a half. Analyzing Treatments The analysis, which reviewed 37 of studies involving thousands of participants, compared the outcomes of these new drugs with older methods. The team note that individuals who shed pounds through lifestyle changes alone typically have a less rapid weight regain—approximately 100 grams monthly—post-intervention. The Reason for the Rapid Rebound Doctors suggest the way of the drugs is key to understanding the heightened rebound. GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness. "Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert. "Withdrawal of this hormone supplement results in appetite is unsuppressed, making excessive eating much more probable." A Chronic Issue? Health authorities suggest the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications. Many experts say that, due to the likelihood of weight regain, the therapy should be considered life-long. This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the long-term character of obesity," comparing it to managing conditions like hypertension. Patient Testimonies Users who have discontinued the jabs explain a intense resurgence of hunger. "It was like a trigger activating and I was suddenly ravenous," said an individual. This difficulty is exacerbated if users have not developed sustainable dietary or behavioural modifications during treatment. Widespread Use Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow. Adoption is higher among females than men. The middle-aged demographic shows the highest usage rates. Many obtain the medications through private prescriptions rather than the NHS. Ultimately, clinicians caution that while these medications are effective tools for shedding pounds, they are not a permanent fix and maintained weight loss likely depends on integrated behavioural support.
Weight management often requires ongoing approaches. Fresh analysis reveals that patients who come off new weight-loss injections like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens. Published data in a prominent medical journal shows that while obese individuals can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit. "People using such drugs must be cognizant of the danger of rapid weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb. That rate of recovery suggests a return to starting weight within about a year and a half. Analyzing Treatments The analysis, which reviewed 37 of studies involving thousands of participants, compared the outcomes of these new drugs with older methods. The team note that individuals who shed pounds through lifestyle changes alone typically have a less rapid weight regain—approximately 100 grams monthly—post-intervention. The Reason for the Rapid Rebound Doctors suggest the way of the drugs is key to understanding the heightened rebound. GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness. "Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert. "Withdrawal of this hormone supplement results in appetite is unsuppressed, making excessive eating much more probable." A Chronic Issue? Health authorities suggest the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications. Many experts say that, due to the likelihood of weight regain, the therapy should be considered life-long. This perspective is echoed by pharmaceutical companies, who note that the findings "underscore the long-term character of obesity," comparing it to managing conditions like hypertension. Patient Testimonies Users who have discontinued the jabs explain a intense resurgence of hunger. "It was like a trigger activating and I was suddenly ravenous," said an individual. This difficulty is exacerbated if users have not developed sustainable dietary or behavioural modifications during treatment. Widespread Use Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow. Adoption is higher among females than men. The middle-aged demographic shows the highest usage rates. Many obtain the medications through private prescriptions rather than the NHS. Ultimately, clinicians caution that while these medications are effective tools for shedding pounds, they are not a permanent fix and maintained weight loss likely depends on integrated behavioural support.